The emerging treatment landscape of targeted therapy in non-small-cell lung cancer.

Yuan M, Huang LL, Chen JH, Wu J, Xu Q. · 2019

Read The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. by Yuan M, Huang LL, Chen JH, Wu J, Xu Q. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6914774.txt.

Introduction

Yuan and co-authors review targeted therapy for non-small-cell lung cancer. Their review appeared in Signal Transduction and Targeted Therapy. Lung cancer is among the most common cancers worldwide. In 2018, over two million new cases were found. Over 1.7 million deaths were blamed on it.

The authors survey recent trials and target pathways. Key routes include EGFR and PI3K/AKT/mTOR. They also cover RAS-MAPK and NTRK/ROS1. Drugs that block these routes now guide care for many patients. The review explains why tumours gain drug resistance. It also looks at third-generation EGFR drugs. Future gains, they argue, will come from mixing targeted drugs with immunotherapy and chemotherapy.

Catalog record

CREATORYuan M, Huang LL, Chen JH, Wu J, Xu Q.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE92 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6914774

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

The emerging treatment landscape of targeted therapy in non-small-cell lung cancer By Min Yuan, Li-Li Huang, Jian-Hua Chen, Jie Wu, Qing Xu Published in: Signal Transduction and Targeted Therapy DOI: 10.1038/s41392-019-0099-9 ABSTRACT Abstract Lung cancer is one of the most common cancer in the world. In 2018, there were over 2 million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer. Targeted therapy has emerged as an important mean of the disease management for patients with non-small-cell lung cancer (NSCLC). Herein, we review and analyze recent literature, discuss the targeting pathways and ongoing clinical trials in lung cancer. Chemotherapy is no longer the best available treatment for all patients. Therapeutic decisions should be guided by an understanding of the molecular features of patient’s tumor tissues. The future gains will likely emerge from finding optimal ways of combining targeted therapy, immunotherapy, and chemotherapy. Subject terms: Lung cancer, Target identification INTRODUCTION Lung cancer is one of the most deadly and common types of cancer in the world.1 In 2018, there are over 1.7 million people died from lung cancer.2 Based on cell origin, about 80–85% are of non-small-cell lung cancer (NSCLC).3 NSCLC is further divided into lung adenocarcinomas, squamous cell carcinoma and large cell carcinoma based on their histological features.4 With the advent of genomic medicine, precisionlized oncology has helped improve treatment outcomes and quality of life compared to traditional chemotherapy.5 Advances in the knowledge of pathways, technologies for detecting actionable genetic lesions, and newly developed drugs to block the activities of the pathways in recent years have allowed the physicians to tailor the treatment options.6 In lung adenocarcinoma, a number of targetable major pathways have been identified, such as EGFR, PI3K/AKT/mTOR, RAS–MAPK, and NTRK/ROS1 pathways.7–10 Many drugs targeting these pathways have been developed and shown clinical benefits.11 Some of them have now replaced chemotherapy as the first line treatment, such as EGFR inhibitors erlotinib, gefitinib, PI3K/AKT/mTOR inhibitors everolimus, and NTRK/ROS1 inhibitors entrectinib.17–20 Nevertheless, while target therapy in NSCLC has provided disease control, the tumors inevitably develop drug resistance. Understanding resistance mechanisms and developing combinational therapies are essential for improving the treatment outcomes.16 Mechanisms of drug resistance in NSCLC have been identified such as TK domain mutation (T790M), MET amplification, RAS mutation.17–20 Other target therapy drugs are in clinical development and have shown promising clinical results to drug resistance, such as third-generation EGFR-TKIs (Osimertinib) which could active and target both EGFR sensitive and T790M resistant mutation.21 With the emergence of immunological checkpoint inhibitors, many NSCLC patients are responsive to antibodies such as the anti-PD1 antibodies nivolumab and pembrolizumab.22 In addition, some studies have reported that some targeted therapies with immunotherapies are efficacious in NSCLC.23 Therefore, this review will focus on the gene mutations in important pathways in NSCLC, and discussed emerging therapies for these tumors (Fig. 1). [Figure: Therapies targeting the key oncogenic signaling pathways in lung cancer.There are several abnormal signaling and cell physiology-related pathways in lung cancer. Drugs targeting these abnormal pathways are depicted schematically. These drugs include agents specifically inhibiting components of the EGFR pathway and other family members and/or members of the VEGFR pathways. Other agents in development include inhibitors of the PI3K/AKT/mTOR pathway, the RAS/BRAF/MAPK pathway, and the JAK–STAT pathway.] TARGETING PATHWAYS IN NON-SMALL-CELL LUNG CANCER EGFR pathways EGFR is a member of tyrosine kinase type I receptors family, and its gene is located on the short arm of human chromosome 7.24 In EGFR, there are 28 exons that form a protein that is distributed on the cell membrane of various epithelial cells, where it binds to epidermal growth factor or heparin-binding EGF and regulates the growth of cells.25 By comparison, exon 20 insertions and exon 18-point mutations are less common than exon 19 deletions and exon 21 L858R substitutions in terms of EGFR mutations in NSCLC.26,27 Activation and regulation of EGFR and downstream genes lead to cell proliferation, apoptosis, and angiogenesis.28 Some measures have been developed to target EGFR, such as tyrosine kinase inhibitors (TKIs), BRAF inhibitors.29,30 In past decades, tyrosine kinase inhibitors have been considered efficient drugs in NSCLC and have served as excellent targeted drugs.31 Various agents targeting EGFR have emerged out such as gefitinib, erlotinib, cetuximab and panitumumab.32–34 Some studies demonstrated that the two first-generation EGFR-TKIs (gefitinib and erlotinib) had substantial benefits in terms of PFS compared to chemotherapy as first-line therapy.35 Unfortunately, the OS in advanced NSCLC patients was not obviously affected by EGFR-TKI treatment after chemotherapy.36 Some studies have shown that patients develop drug resistance after receiving first-generation EGFR-TKI therapy for 10–14 months.37,38 Mechanisms of drug resistance of first-generation EGFR-TKI in NSCLC have been identified such as TK domain mutation (T790M), MET amplification, RAS mutation.39–41 TK domain mutation (T790M) is described as the most common acquired resistance mutation in the NSCLC patients.42,43 A subset of NSCLC patients with the T790M mutation have never underwent EGFR-TKI treatment.44,45 These finding suggest that the T790M mutation is a potential target in NSCLC patients.44 Therefore, new measures and therapies need to develop to overcome drug resistance. In recent years, osimertinib has emerged as a third-generation EGFR-TKIs that can active and target both sensitive and resistant (T790M) EGFR mutations.46 In the FLAURA study, the median PFS of NSCLC patients treated with osimertinib (18.9 months) was obviously longer than that in patients treated with first-generation EGFR-TKIs (gefitinib and erlotinib) (10.2 months).47 This group of patients had EGFR exon 19 deletions or L858R mutations in untreated NSCLC that had progressed. Another study (AURA3) showed that the PFS associated with osimertinib was 10.1 months, whereas the PFS associated with pemetrexed/platinum doublet chemotherapy was 4.4 months. The objective response was significantly higher in osimertinib group.23 Though osimertinib has showed promising survival benefits in clinical trials, choice still needs to be made. It is beneficial to consider the optimal sequence of EGFR TKIs in order to maximize their clinical benefit. Osimertinib followed by a first-or-second-generation EGFR-TKI or followed by pemetrexed/platinum doublet chemotherapy might be a rational choice.48–50 There remain debates about sequence of therapy, more clinical trials are required to clarify the most appropriate sequential therapy in patients with EGFR mutation-positive NSCLC. Unfortunately, a study showed that drug resistance to osimertinib has emerged. Among 45 patients, the EGFR C797S mutation, mutations in PIK3CA, KRAS, BRAF, and MET amplification were found.51 In EGFR-mutated NSCLC, 5–20% EGFR-TKI drug-resistant patients developed MET amplification.52 MET amplification increases the proliferation and migration of HCC827 cell line in NSCLC.53 Results showed that aiming at MET amplification could prompt therapeutic efficacy.54 A MET inhibitor (crizotinib or SGX532) could increase the gefitinib sensitive in NSCLC.55 In addition, KRAS, a member of RAS mutation has been identified as the most frequently mutated oncogene in NSCLC.56 Previous studies have shown that KRAS mutation has been identified as a mechanism of EGFR-TKI resistance in NSCLC.57 Thus, therapeutic strategies target to KRAS mutation might be overcome drug resistance and improve the therapeutic efficacy.58 Some KRAS inhibitors have been identified, such as KRAS G12C mutant protein which showed excellent efficacy in vitro.59 Therefore, different therapeutic strategies targeting at EGFR pathway showed various efficacy which overcomes drug resistance and cancer progression. PI3K/AKT/mTOR pathways The PI3K/AKT/mTOR pathway is considered a potential target in NSCLC. The PI3K signaling pathway regulates various

Read the complete text